These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 21909139)

  • 1. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
    Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth.
    Gritsina G; Xiao F; O'Brien SW; Gabbasov R; Maglaty MA; Xu RH; Thapa RJ; Zhou Y; Nicolas E; Litwin S; Balachandran S; Sigal LJ; Huszar D; Connolly DC
    Mol Cancer Ther; 2015 Apr; 14(4):1035-47. PubMed ID: 25646015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
    Colomiere M; Ward AC; Riley C; Trenerry MK; Cameron-Smith D; Findlay J; Ackland L; Ahmed N
    Br J Cancer; 2009 Jan; 100(1):134-44. PubMed ID: 19088723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.
    Sheng WJ; Jiang H; Wu DL; Zheng JH
    Braz J Med Biol Res; 2013 Aug; 46(8):650-8. PubMed ID: 23969971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
    Selvendiran K; Bratasz A; Tong L; Ignarro LJ; Kuppusamy P
    Cell Cycle; 2008 Jan; 7(1):81-8. PubMed ID: 18196976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
    Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
    Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
    Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
    Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.
    Zhang M; Cong Q; Zhang XY; Zhang MX; Lu YY; Xu CJ
    J Cell Physiol; 2019 May; 234(5):6361-6370. PubMed ID: 30229902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
    Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ; Sun ZL; Wu WG; Xing J; He YF; Xin DM; Han P
    Genet Mol Res; 2015 Mar; 14(1):2450-60. PubMed ID: 25867391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
    Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
    Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
    [No Abstract]   [Full Text] [Related]  

  • 12. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
    Zhang L; Chen Y; Li F; Bao L; Liu W
    Front Immunol; 2019; 10():867. PubMed ID: 31105696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
    Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.
    Lo HW; Hsu SC; Xia W; Cao X; Shih JY; Wei Y; Abbruzzese JL; Hortobagyi GN; Hung MC
    Cancer Res; 2007 Oct; 67(19):9066-76. PubMed ID: 17909010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo.
    Kandala PK; Srivastava SK
    Drug Discov Ther; 2012 Apr; 6(2):94-101. PubMed ID: 22622019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
    Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
    Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.
    Carmo CR; Lyons-Lewis J; Seckl MJ; Costa-Pereira AP
    PLoS One; 2011; 6(5):e19861. PubMed ID: 21625473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curcumin-Mediated Apoptotic Cell Death in Papillary Thyroid Cancer and Cancer Stem-Like Cells through Targeting of the JAK/STAT3 Signaling Pathway.
    Khan AQ; Ahmed EI; Elareer N; Fathima H; Prabhu KS; Siveen KS; Kulinski M; Azizi F; Dermime S; Ahmad A; Steinhoff M; Uddin S
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells.
    Duan Z; Ames RY; Ryan M; Hornicek FJ; Mankin H; Seiden MV
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):681-9. PubMed ID: 18587580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer.
    Zhao J; Tan W; Zhang L; Liu J; Shangguan M; Chen J; Zhao B; Peng Y; Cui M; Zhao S
    Biochem Pharmacol; 2021 Aug; 190():114536. PubMed ID: 33794187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.